Skip to main content
. 2017 May 26;24(1):857–866. doi: 10.1080/10717544.2017.1330373

Figure 3.

Figure 3.

(a) Fluorescence in mice administered free DOX-AF750 or RLBN-DOX-AF750, as measured with an in vivo imaging system on days 1, 3, 6 and 9. Free DOX-AF750 or RLBN-DOX-AF750 was intratumorally administered on day 0. (b) Residual DOX in tumors at predetermined times (mean ± SD, n = 5). DOX in the Free DOX group was not detectable at day 9 and 17. DOX-AF750: doxorubicin with Alexa Fluor® 750 dye (AF750); RLBN-DOX-AF750: reversed lipid-based nanoparticles loaded with doxorubicin and AF750; DOX: doxorubicin; RLBN-DOX: reversed lipid-based nanoparticle loaded with doxorubicin; SD: standard deviation. *p < .05, ***p < .001.